Clinical Trial · NCT06657131

Diagnostic Performance of [18F]PSMA-1007 in the Context of Biochemical Recurrence of Prostate Cancer

Overview

Following numerous retrospective studies and Phase-3-Studies with promising results, \[18F\]PSMA-1007 has been approved by european authorities. Therefore, it is a growing deployment of this diagnostic method anticipated. This study aims to investigate the diagnostic performance and clinical impact in a real-world-evidence in the context of regular clinical care. The evidence generated by this approach is supposed to assist in optimizing the management of prostate cancer patients.

Sponsor

Heinrich-Heine University

Contacts

Eduards Mamlins, Medical Doctor (CONTACT)

eduards.mamlins@med.uni-duesseldorf.de

(+49)211 8108069

Emil Novruzov, Medical Doctor (CONTACT)

emil.novruzov@med.uni-duesseldorf.de

(+49)211 8118540

Frederik Lars Giesel, Prof. Dr., Medical Doctor (STUDY_CHAIR)

ClinicalTrials.gov

NCT06657131

Drug / Compound

PSMA-1007

Isotope(s):

Target(s):

PSMA

Ligand Class: Small Molecules

Linker: naphthalene-based linker region

Eligibility

Inclusion

Conduct of \[18F\]PSMA-1007 PET Imaging in the context of regular clinical care

Exclusion

Technical Flaws in the acquisition protocol